Prescribing Information Summary of Product Characteristics
digoxin immune fab digifab logo DIGIFab

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

Order DIGIFab®
01865 904141

Guideline

DIGIFab® Should Be Stocked
for Immediate Availability1,2*

The Royal College of Emergency Medicines and National Poisons Information Service (RCEM & NPIS) Guideline on Antidote Availability for Emergency Departments:

5 vials* of DIGIFab® should be immediately available in the emergency department, or any areas where poisoned patients are initially treated, for administration on patient arrival

View Guideline within NPIS Antidotes
View Guideline within NPIS Antidotes
  • It is important that antidotes such as DIGIFab® are available in a timely fashion to ensure optimal patient care.

Recommended minimum stocking levels based on the amount required to initiate treatment for an adult patient in the emergency department and to continue treatment for the first 24 hours. Higher stock levels may be required; individual departments should determine the amount stocked based on the epidemiology of poisoning presentations to their department.


digoxin toxicity rapid treatment image

For known (or strongly suspected) life-threatening digoxin toxicity or cardiac glycoside poisoning, think R.A.P.I.D.1-3

Recognize. Act. Promptly Infuse DIGIFab®.

View Efficacy Data

* DIGIFab® is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity or cardiac glycoside poisoning associated with ventricular arrhythmias or bradyarrhythmias unresponsive to atropine where measures beyond withdrawal of digoxin or cardiac glycosides and correction of serum electrolyte abnormalities are considered necessary.3

References

  1. Royal College of Emergency Medicines and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments. Guideline available from RCEM, at: https://rcem.ac.uk/clinical-guidelines/ Accessed December 2024.
  2. Levine MD, O’Connor A. UpToDate. Updated January 2020. Available at: https://www.uptodate.com/contents/digitalis-cardiac-glycoside-poisoning. Accessed December 2024.
  3. DIGIFab Digoxin Immune Fab (ovine) Summary of Product Characteristics (SmPC).